Lisata Therapeutics, Inc. (LSTA) stock
Close on Nov 13, 2026Market cap $10.90MP/E –Yield –
Lisata Therapeutics, Inc. saw revenue fall 90.7% to $100.00K over the twelve months to Sep 30, 2026. Free cash flow was -$21.66M. At the latest close the market valued the company at $10.90M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.90M
- P/E ratio
- –
- Price to sales
- 109.03
- Price to book
- 1.43
- Dividend yield
- –
- Free cash flow yield
- -198.68%
Fundamentals
- Revenue
- $100.00K
- Net income
- -$17.16M
- EPS, diluted
- -$1.89
- Free cash flow
- -$21.66M
- Book value per share
- $0.82
- Diluted shares
- 9M
Trading
- Previous close
- $1.28
- Open
- $1.25
- Day's range
- $1.20 – $1.26
- Volume
- 104,863
- Average volume (20 days)
- 120,593
- Beta (5 years)
- 0.74
- 52-week range
- $0.96 – $5.07
- RSI (14 days)
- 54.1
- Volatility (1 year)
- 130.6%
- Relative volume
- 0.42×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | LSTA | S&P 500 | Difference | LSTA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.0% | -3.0% | +15.1 pts | ||
| 3 months | +7.1% | -2.8% | +9.9 pts | ||
| Year to date | -34.9% | +11.5% | −46.4 pts | ||
| 1 year | -41.5% | +13.5% | −55.0 pts | ||
| 3 years | -43.6% | +77.7% | −121.3 pts | -17.4% | +21.1% |
| 5 years | -92.3% | +72.6% | −164.9 pts | -40.1% | +11.5% |
| 10 years | -97.6% | +308.2% | −405.8 pts | -31.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lisata Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- News
- Results
About Lisata Therapeutics
Pharmaceutical Preparations
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing treatments for solid tumors and other serious conditions. The company's lead investigational drug candidate is certepetide, which operates via the C-end rule active transport pathway to facilitate deeper penetration of anti-cancer therapies into tumors while altering the tumor microenvironment. Lisata collaborates with biopharmaceutical partners and researchers to evaluate the drug alongside chemotherapy, immunotherapy, and RNA-based treatments for cancer patients.
Company profile, executives and historyLisata Therapeutics stock: common questions
What is Lisata Therapeutics's stock price?
LSTA closed at $1.21 on Nov 13, 2026, down 5.47% on the day. Over the past 52 weeks it traded between $0.96 and $5.07.
What is Lisata Therapeutics's market cap?
Lisata Therapeutics was worth $10.90M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is LSTA's P/E ratio?
Lisata Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.89), so it has no meaningful P/E ratio.
How much revenue does Lisata Therapeutics make?
Lisata Therapeutics reported revenue of $100.00K for the twelve months to Sep 30, 2026, down 90.7% from a year earlier.
Does Lisata Therapeutics pay a dividend?
No. Lisata Therapeutics has not paid a cash dividend over the last twelve months.
How has LSTA stock performed over the past year?
Including dividends, LSTA returned -41.5% over the past year, against +13.5% for the S&P 500.
How many LSTA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.43% of the float, or 1.0 days of average trading volume.
Who are Lisata Therapeutics's competitors?
Companies most similar to Lisata Therapeutics by business, industry and size include KZIA, SER, SNGX, IXHL, HIND.
See a number that looks wrong?